Kidney Cancer,
Journal Year:
2023,
Volume and Issue:
7(1), P. 137 - 145
Published: Dec. 18, 2023
Background:
Ipilimumab
plus
nivolumab
is
approved
as
a
first-line
treatment
for
intermediate
or
poor
risk
metastatic
renal
cell
carcinoma
(mRCC).
However,
∼35%
of
patients
progress
within
six
months
on
ipilimumab
nivolumab,
and
no
validated
genomic
biomarkers
predict
the
benefit.
In
this
study,
we
explore
transcriptomic
differences
among
with
clear
mRCC
who
either
did
not
experience
clinical
benefit
from
therapy.
Method:
Patients
IMDC
scores,
available
tumor
whole
exome
with/without
transcriptome
sequencing
before
starting
systemic
therapy
were
included.
developed
complete
response,
partial
stable
disease
at
least
after
initiating
categorized
into
‘clinical
benefit’
group,
whereas
rest
classified
‘no
benefit.’
Genomic
alteration
frequencies
between
groups
assessed
chi-square
test.
Differentially
expressed
genes
gene
sets
identified
via
DeSeq2
GSEA
v4.2.3,
respectively.
Result:
53
(37
16
benefit)
eligible
No
significant
difference
was
found
in
these
groups.
Baseline
data
14
(9
5
benefit).
The
apical
surface
pathways
downregulated
by
KRAS
signaling
enriched
inflammatory
group.
Conclusion:
These
findings
suggest
that
specific
expression
RNA
could
serve
potential
biomarker
response
to
Cancers,
Journal Year:
2024,
Volume and Issue:
16(10), P. 1896 - 1896
Published: May 16, 2024
Background:
This
study
aimed
to
systematically
review
case
reports
documenting
rare
adverse
events
in
patients
with
small
cell
lung
cancer
(SCLC)
following
the
administration
of
immune
checkpoint
inhibitors
(ICIs).
Methods:
A
systematic
literature
was
conducted
identify
detailing
previously
unreported
drug
reactions
ICIs
SCLC.
The
scope
reviewed
restricted
studies
on
SCLC
published
up
31
December
2023.
Results:
We
analyzed
twenty-four
ICI
use
for
There
were
six
atezolizumab,
four
durvalumab,
and
three
from
monotherapy
nivolumab.
Reports
involving
combination
treatments
most
frequent,
a
total
six,
predominantly
using
nivolumab
ipilimumab.
Additionally,
there
one
report
each
pembrolizumab,
nofazinilimab,
sintilimab,
tislelizumab,
toripalimab.
collected
detailed
information
clinical
course,
including
patient
disease
characteristics,
symptoms,
treatment
event,
recovery
status.
Among
included
reports,
21
out
24
(87.5%)
had
extensive-stage
when
initiating
therapy,
only
1
diagnosed
limited-stage
Respiratory
system
common,
seven
cases,
followed
by
neurological,
endocrinological,
gastroenterological
events.
Three
documented
across
multiple
systems
single
patient.
In
showed
symptom
improvement;
however,
reported
cases
where
either
expired
without
improvement
or
experienced
sequelae.
Conclusions:
Efforts
develop
reliable
biomarkers
predicting
irAEs
continue,
ongoing
research
enhance
predictive
precision.
Immunotherapy
presents
diverse
unpredictable
events,
underscoring
need
advanced
diagnostic
tools
multidisciplinary
approach
improve
management.
Thoracic Cancer,
Journal Year:
2025,
Volume and Issue:
16(9)
Published: May 1, 2025
ABSTRACT
Triple‐negative
breast
cancer
(TNBC),
accounting
for
about
10%–20%
of
all
cases,
is
characterized
by
its
aggressive
nature,
high
recurrence
rates,
and
poor
prognosis.
Unlike
other
subtypes,
TNBC
lacks
hormone
receptors
specific
molecular
targets,
limiting
therapeutic
options.
In
recent
years,
immune
checkpoint
inhibitors
(ICIs)
have
shown
promise
in
treating
targeting
evasion
mechanisms.
Despite
these
advancements,
several
issues
remain
unresolved,
including
low
response
rates
programmed
cell
death
ligand
1
(PD‐L1)
negative
subtypes
the
challenge
predicting
which
patients
will
benefit
from
ICIs.
Consequently,
there
growing
interest
identifying
reliable
biomarkers
beyond
PD‐L1
expression.
This
review
synthesizes
studies
to
provide
a
comprehensive
perspective
on
ICI
therapy
TNBC,
clarifying
status
single‐agent
therapies
combination
strategies,
emphasizing
need
further
research
into
biomarkers.
These
insights
clues
more
personalized
effective
treatment
approaches,
ultimately
aiming
improve
clinical
outcomes
with
TNBC.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1181 - 1181
Published: Sept. 7, 2024
The
programmed
death-1/programmed
death-ligand
1
(PD-1/PD-L1)
immune
checkpoint
constitutes
an
inhibitory
pathway
best
known
for
its
regulation
of
cluster
differentiation
8
(CD8)+
T
cell-mediated
responses.
Engagement
PD-L1
with
PD-1
expressed
on
CD8+
cells
activates
downstream
signaling
pathways
that
culminate
in
cell
exhaustion
and/or
apoptosis.
Physiologically,
these
immunosuppressive
effects
exist
to
prevent
autoimmunity,
but
cancer
exploit
this
by
overexpressing
facilitate
escape.
Intravenously
(IV)
administered
inhibitors
(ICIs)
block
the
interaction
between
PD-1/PD-L1
have
achieved
great
success
reversing
and
promoting
tumor
regression
various
malignancies.
However,
ICIs
can
cause
immune-related
adverse
events
(irAEs)
due
off-tumor
toxicities
which
limits
their
therapeutic
potential.
Therefore,
considerable
effort
has
been
channeled
into
exploring
alternative
delivery
strategies
enhance
tumor-directed
reduce
irAEs.
Here,
we
briefly
describe
PD-1/PD-L1-targeted
immunotherapy
associated
We
then
provide
a
detailed
review
approaches,
including
locoregional
(LDD)-,
oncolytic
virus
(OV)-,
nanoparticle
(NP)-,
ultrasound
microbubble
(USMB)-mediated
are
currently
under
investigation
enhancing
tumor-specific
minimize
toxic
effects.
conclude
commentary
key
challenges
methods
potential
mitigate
them.
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(9), P. 2438 - 2438
Published: Aug. 31, 2023
Immune
checkpoint
inhibitors
have
become
the
standard
of
care
in
treatment
metastatic
non-small-cell
lung
cancer
(NSCLC).
The
combination
nivolumab
plus
ipilimumab
and
chemotherapy
has
been
shown
to
improve
outcomes
terms
overall
survival
(OS)
progression-free
(PFS).
aim
this
study
was
evaluate
NSCLC
treated
routine
practice
on
regimen
CheckMate
9LA
protocol.
Medical
records
58
patients
at
Soroka
Bnai
Zion
Centers
between
May
2020
February
2022
were
analyzed.
All
with
a
platinum-based
combined
immunotherapy
every
three
weeks
6
weeks.
received
2–3
cycles
according
physician’s
choice:
cisplatin
or
carboplatin
either
pemetrexed
paclitaxel.
median
PFS
10.2
months,
longer
than
that
trial
(6.7
months).
Adenocarcinoma
exhibited
higher
OS
13.7
(range
5–33)
months
squamous
cell
carcinoma
(SCC)
12.3
(5–20)
10.3
(4–33)
while
had
9.2
(4–18)
months.
Patients
whose
programmed
death
ligand-1
(PD-L1)
tumor
expression
level
≥1%
showed
those
PD-L1
less
1%.
Treatment-related
adverse
events
(TRAEs)
reported
93.1%
patients,
mostly
grade
1
severity.
first-line
can
be
given
safely
clinical
practice,
results
comparable
achieved
trials
regimen.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Dec. 4, 2023
This
study
amied
to
investigate
the
prognostic
characteristics
of
triple
negative
breast
cancer
(TNBC)
patients
by
analyzing
B
cell
marker
genes
based
on
single-cell
and
bulk
RNA
sequencing.
Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 5, 2024
There
are
no
effective
treatment
options
for
patients
with
poor
performance
status
and
limited
liver
reserve,
classified
as
Child-Pugh
Grade
B
C.
A
61-year-old
man
a
prior
medical
history
of
hepatitis
C
virus
infection
was
admitted
to
the
hospital
abdominal
distension
significant
ascites.
He
diagnosed
stage
IVB
hepatocellular
carcinoma
(HCC),
characterized
by
multiple
metastases
lymph
nodes,
lungs,
bones.
After
receiving
combined
immune
therapy,
including
dendritic
cell
therapy
targeting
WT1
α-Galactosylceramide,
natural
killer
cells,
Nivolumab,
patient
showed
improvement
in
HCC
reserve
function
followed
standard
treatment.
Combined
is
potentially
an
important
option
advanced
function,
especially
relatively
young
patients.
Bulletin of Siberian Medicine,
Journal Year:
2024,
Volume and Issue:
23(2), P. 101 - 113
Published: July 10, 2024
Over
the
past
two
decades,
targeted
therapy
has
actively
developed
and,
demonstrating
impressive
clinical
results,
gained
an
increasingly
important
role
in
treatment
of
cancer.
This
was
facilitated
to
a
large
extent
by
in-depth
understanding
mechanisms
cancer
development,
and
mainly,
discovery
molecular
targets.
Despite
fact
that
can
radically
change
results
prognosis
disease
course
some
cases,
its
effectiveness
is
sometimes
replaced
drug
resistance,
others.
The
authors
lecture
analyzed
systematized
therapeutic
approaches
addressing
number
targets
are
key
for
implementing
specific
stage
human
tumor
pathogenesis.
These
include
maintaining
chronic
proliferative
signaling,
promoting
evasion
cell
growth
suppressors,
inducing
angiogenesis,
forming
immune
surveillance,
activating
invasion
metastasis.
presented
drugs
used
Russian
Federation,
including
antibody-based
small
molecule
tyrosine
kinase
inhibitors.
It
also
interaction
between
these
their
targets,
as
well
possible
factors
developing
resistance
ways
overcome
mechanisms.
Kidney Cancer,
Journal Year:
2023,
Volume and Issue:
7(1), P. 137 - 145
Published: Dec. 18, 2023
Background:
Ipilimumab
plus
nivolumab
is
approved
as
a
first-line
treatment
for
intermediate
or
poor
risk
metastatic
renal
cell
carcinoma
(mRCC).
However,
∼35%
of
patients
progress
within
six
months
on
ipilimumab
nivolumab,
and
no
validated
genomic
biomarkers
predict
the
benefit.
In
this
study,
we
explore
transcriptomic
differences
among
with
clear
mRCC
who
either
did
not
experience
clinical
benefit
from
therapy.
Method:
Patients
IMDC
scores,
available
tumor
whole
exome
with/without
transcriptome
sequencing
before
starting
systemic
therapy
were
included.
developed
complete
response,
partial
stable
disease
at
least
after
initiating
categorized
into
‘clinical
benefit’
group,
whereas
rest
classified
‘no
benefit.’
Genomic
alteration
frequencies
between
groups
assessed
chi-square
test.
Differentially
expressed
genes
gene
sets
identified
via
DeSeq2
GSEA
v4.2.3,
respectively.
Result:
53
(37
16
benefit)
eligible
No
significant
difference
was
found
in
these
groups.
Baseline
data
14
(9
5
benefit).
The
apical
surface
pathways
downregulated
by
KRAS
signaling
enriched
inflammatory
group.
Conclusion:
These
findings
suggest
that
specific
expression
RNA
could
serve
potential
biomarker
response
to
